Version 4 2022-02-28, 22:31Version 4 2022-02-28, 22:31
Version 3 2022-02-24, 21:57Version 3 2022-02-24, 21:57
Version 2 2022-02-24, 21:57Version 2 2022-02-24, 21:57
Version 1 2022-02-23, 14:56Version 1 2022-02-23, 14:56
figure
posted on 2022-02-28, 22:31authored byEmily K Sims, Rachel EJ Besser, Colin Dayan, Cristy Geno Rasmussen, Carla Greenbaum, Kurt J Griffin, William Hagopian, Mikael Knip, Anna E. Long, Frank Martin, Chantal Mathieu, Marian Rewers, Andrea K. Steck, John M Wentworth, Stephen S. Rich, Olga Kordonouri, Anette-Gabriele Ziegler, Kevan C. Herold, NIDDK Type 1 Diabetes TrialNet Study Group
Most screening programs to
identify individuals at risk for type 1 diabetes have targeted relatives of
people living with the disease to improve yield and feasibility. However, ~90%
of those who develop type 1 diabetes do not have a family history. Recent
successes in disease modifying therapies to impact the course of early-stage disease
have ignited the consideration of the need for and feasibility of population
screening to identify those at increased risk. Existing population screening
programs rely on genetic or autoantibody
(AA) screening, and these have yielded significant information about disease
progression and approaches for timing for screening in clinical practice. At
the March 2021 Type 1 Diabetes TrialNet Steering Committee meeting, a session
was held in which ongoing efforts for screening in the general population were
discussed. This report reviews the background of these efforts and the details of
those programs. Additionally, we present hurdles that need to be addressed for
successful implementation of population screening and provide initial
recommendations for individuals with positive screens so that standardized
guidelines for monitoring and follow-up can be established.
Funding
U.S. Department of Health and Human Services > National Institutes of Health > National Institute of Diabetes and Digestive and Kidney Diseases U01DK106993